{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:52:52Z","timestamp":1793134372110,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Once-daily (od), low-dose aspirin (75\u2013100\u2009mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100\u2009mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A<jats:sub>2<\/jats:sub> production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB<jats:sub>2<\/jats:sub>, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB<jats:sub>2<\/jats:sub> as a reliable end point for dose-finding studies of novel aspirin regimens.<\/jats:p>","DOI":"10.1038\/s41408-018-0078-3","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T11:27:57Z","timestamp":1527852477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting"],"prefix":"10.1038","volume":"8","author":[{"given":"Valerio","family":"De Stefano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Tosetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Soldati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Beggiato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Carpenedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Cavalca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Dragani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Elli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lanzarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lissandrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ranalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luigia","family":"Randi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ricco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Timillero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Turnu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rodeghiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Patrono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"78_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0041-8","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi, A., Vannucchi, A. M. & Barbui, T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 8, 2 (2018).","journal-title":"Blood Cancer J."},{"key":"78_CR2","first-page":"133","volume":"11","author":"L Ryden","year":"2013","unstructured":"Ryden, L. et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. Diab. Vasc. Dis. Res. 11, 133\u2013173 (2013).","journal-title":"Diab. Vasc. Dis. Res."},{"key":"78_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V De Stefano","year":"2008","unstructured":"De Stefano, V. et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93, 372\u2013380 (2008).","journal-title":"Haematologica"},{"key":"78_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937\u2013951 (2009).","journal-title":"Blood"},{"key":"78_CR5","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00432-015-1983-5","volume":"141","author":"MA Deadmond","year":"2015","unstructured":"Deadmond, M. A. & Smith-Gagen, J. A. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. J. Cancer Res. Clin. Oncol. 141, 2131\u20132138 (2015).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"78_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","volume":"92","author":"O Moulard","year":"2014","unstructured":"Moulard, O. et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur. J. Haematol. 92, 289\u2013297 (2014).","journal-title":"Eur. J. Haematol."},{"key":"78_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ejh.12788","volume":"98","author":"C Roaldsnes","year":"2017","unstructured":"Roaldsnes, C., Holst, R., Frederiksen, H. & Ghanima, W. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur. J. Haematol. 98, 85\u201393 (2017).","journal-title":"Eur. J. Haematol."},{"key":"78_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.23690","volume":"89","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh, G. J. et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am. J. Hematol. 89, 581\u2013587 (2014).","journal-title":"Am. J. Hematol."},{"key":"78_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","volume":"121","author":"C Patrono","year":"2013","unstructured":"Patrono, C., Rocca, B. & De Stefano, V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 121, 1701\u20131711 (2013).","journal-title":"Blood"},{"key":"78_CR10","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","volume":"33","author":"M Hultcrantz","year":"2015","unstructured":"Hultcrantz, M. et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J. Clin. Oncol. 33, 2288\u20132295 (2015).","journal-title":"J. Clin. Oncol."},{"key":"78_CR11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1055\/s-0038-1649916","volume":"74","author":"B Rocca","year":"1995","unstructured":"Rocca, B. et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb. Haemost. 74, 1225\u20131230 (1995).","journal-title":"Thromb. Haemost."},{"key":"78_CR12","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","volume":"115","author":"A Dragani","year":"2009","unstructured":"Dragani, A. et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 115, 1054\u20131061 (2009).","journal-title":"Blood"},{"key":"78_CR13","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood.V99.7.2612","volume":"99","author":"JF Viallard","year":"2002","unstructured":"Viallard, J. F. et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 99, 2612\u20132614 (2002).","journal-title":"Blood"},{"key":"78_CR14","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","volume":"119","author":"S Pascale","year":"2012","unstructured":"Pascale, S. et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 119, 3595\u20133603 (2012).","journal-title":"Blood"},{"key":"78_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1172\/JCI112341","volume":"77","author":"C Patrono","year":"1986","unstructured":"Patrono, C. et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J. Clin. Invest. 77, 590\u2013594 (1986).","journal-title":"J. Clin. Invest."},{"key":"78_CR16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","volume":"105","author":"JW Eikelboom","year":"2002","unstructured":"Eikelboom, J. W. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105, 1650\u20131655 (2002).","journal-title":"Circulation"},{"key":"78_CR17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1160\/TH16-05-0349","volume":"116","author":"G Petrucci","year":"2016","unstructured":"Petrucci, G. et al. Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. Thromb. Haemost. 116, 891\u2013896 (2016).","journal-title":"Thromb. Haemost."},{"key":"78_CR18","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","volume":"116","author":"A Alvarez-Larran","year":"2010","unstructured":"Alvarez-Larran, A. et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116, 1205\u20131210 (2010).","journal-title":"Blood"},{"key":"78_CR19","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3324\/haematol.2016.146654","volume":"101","author":"A Alvarez-Larran","year":"2016","unstructured":"Alvarez-Larran, A. et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 101, 926\u2013931 (2016).","journal-title":"Haematologica"},{"key":"78_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi, R. et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 350, 114\u2013124 (2004).","journal-title":"N. Engl. J. Med."},{"key":"78_CR21","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono, C., Garcia Rodriguez, L. A., Landolfi, R. & Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353, 2373\u20132383 (2005).","journal-title":"N. Engl. J. Med."},{"key":"78_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","volume":"53","author":"F Santilli","year":"2009","unstructured":"Santilli, F. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance\u201d. J. Am. Coll. Cardiol. 53, 667\u2013677 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"78_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","volume":"17","author":"C Patrono","year":"1980","unstructured":"Patrono, C. et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res. 17, 317\u2013327 (1980).","journal-title":"Thromb. Res."},{"key":"78_CR24","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Antithrombotic Trialists","year":"2009","unstructured":"Antithrombotic Trialists, C. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849\u20131860 (2009).","journal-title":"Lancet"},{"key":"78_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.thromres.2011.09.017","volume":"129","author":"JG Dillinger","year":"2012","unstructured":"Dillinger, J. G. et al. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb. Res. 129, 91\u201394 (2012).","journal-title":"Thromb. Res."},{"key":"78_CR26","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/eurheartj\/ehv366","volume":"36","author":"B Rocca","year":"2015","unstructured":"Rocca, B. & Patrono, C. Platelet progenitors: the hidden drug target. Eur. Heart J. 36, 3211\u20133213 (2015).","journal-title":"Eur. Heart J."},{"key":"78_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/cpt.702","volume":"102","author":"V Cavalca","year":"2017","unstructured":"Cavalca, V. et al. On-pump cardiac surgery enhances platelet renewal and impairs aspirin pharmacodynamics: effects of improved dosing regimens. Clin. Pharmacol. Ther. 102, 849\u2013858 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"78_CR28","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","volume":"10","author":"B Rocca","year":"2012","unstructured":"Rocca, B. et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J. Thromb. Haemost. 10, 1220\u20131230 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"78_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/CIRCULATIONAHA.105.505636","volume":"113","author":"LK Newby","year":"2006","unstructured":"Newby, L. K. et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113, 203\u2013212 (2006).","journal-title":"Circulation"},{"key":"78_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","volume":"143","author":"HC Diener","year":"1996","unstructured":"Diener, H. C. et al. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1\u201313 (1996).","journal-title":"J. Neurol. Sci."},{"key":"78_CR31","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","volume":"357","author":"G Davi","year":"2007","unstructured":"Davi, G. & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482\u20132494 (2007).","journal-title":"N. Engl. J. Med."},{"key":"78_CR32","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1172\/JCI111089","volume":"72","author":"GA FitzGerald","year":"1983","unstructured":"FitzGerald, G. A., Brash, A. R., Oates, J. A. & Pedersen, A. K. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J. Clin. Invest. 72, 1336\u20131343 (1983).","journal-title":"J. Clin. Invest."},{"key":"78_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1160\/TH13-10-0844","volume":"112","author":"V Cavalca","year":"2014","unstructured":"Cavalca, V. et al. In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. Thromb. Haemost. 112, 118\u2013127 (2014).","journal-title":"Thromb. Haemost."},{"key":"78_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman, S., Kearon, C. & Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3, 692\u2013694 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"78_CR35","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz, S., Ahmad, D., Spyropoulos, A. C., Schulman, S. & Subcommittee on Control of A. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J. Thromb. Haemost. 13, 2119\u20132126 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"78_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1572-0241.2002.05419.x","volume":"97","author":"L Rabeneck","year":"2002","unstructured":"Rabeneck, L. et al. Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am. J. Gastroenterol. 97, 32\u201339 (2002).","journal-title":"Am. J. Gastroenterol."},{"key":"78_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber, R. et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 118, 401\u2013408 (2011).","journal-title":"Blood"},{"key":"78_CR38","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"78_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2337\/db15-0936","volume":"65","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi, F. et al. In vivo platelet activation and aspirin responsiveness in type 1. Diabetes 65, 503\u2013509 (2016).","journal-title":"Diabetes"},{"key":"78_CR40","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui, T. et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J. Clin. Oncol. 29, 3179\u20133184 (2011).","journal-title":"J. Clin. Oncol."},{"key":"78_CR41","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi, G. et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 26, 716\u2013719 (2012).","journal-title":"Leukemia."},{"key":"78_CR42","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","volume":"72","author":"C Patrono","year":"1985","unstructured":"Patrono, C. et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72, 1177\u20131184 (1985).","journal-title":"Circulation"},{"key":"78_CR43","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/ATVBAHA.110.219527","volume":"31","author":"M Holinstat","year":"2011","unstructured":"Holinstat, M. et al. Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2alpha differently for cyclooxygenase-1 and 12-lipoxygenase catalysis. Arterioscler. Thromb. Vasc. Biol. 31, 435\u2013442 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"78_CR44","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1172\/JCI110576","volume":"69","author":"P Patrignani","year":"1982","unstructured":"Patrignani, P., Filabozzi, P. & Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69, 1366\u20131372 (1982).","journal-title":"J. Clin. Invest."},{"key":"78_CR45","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","volume":"120","author":"AL Frelinger 3rd","year":"2009","unstructured":"Frelinger, A. L. 3rd et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120, 2586\u20132596 (2009).","journal-title":"Circulation"},{"key":"78_CR46","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1161\/CIRCULATIONAHA.111.085464","volume":"125","author":"JL Reny","year":"2012","unstructured":"Reny, J. L. et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 125, 3201\u20133210 (2012).","journal-title":"Circulation"},{"key":"78_CR47","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/09537104.2015.1072147","volume":"27","author":"C Brun","year":"2016","unstructured":"Brun, C. Aspirin response: differences in serum thromboxane B2 levels between clinical studies. Platelets 27, 196\u2013202 (2016).","journal-title":"Platelets"},{"key":"78_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2018.01.010","volume":"163","author":"JJK van Diemen","year":"2018","unstructured":"van Diemen, J. J. K. et al. Influence of pre-analytical time and temperature conditions on serum thromboxane B2 levels. Thromb. Res. 163, 1\u20135 (2018).","journal-title":"Thromb. Res."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0078-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0078-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0078-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:35:26Z","timestamp":1671536126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0078-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["78"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0078-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]},"assertion":[{"value":"15 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.D.S. has received consulting and lecture fees from Amgen, Bayer, Celgene, Novartis, and institutional research grants from Novartis; B.R. has received consulting and lecture fees from Amgen, Bayer, Celgene, Daiichi Sankyo Italia, Novartis, and Sanofi; A.Ra. has received consulting and lecture fees from Amgen, Bristol Mayer Squibb, Celgene, Italfarmaco, Novartis, Pfizer, and Roche; F.P. has received consulting and lecture fees from Novartis; A.M.V. has received consulting and lecture fees from Italfarmaco, Novartis, Shire, and institutional research grants from Novartis; C.P. has received consulting and lecture fees from Amgen, AstraZeneca, Bayer, and GlaxoSmithKline, and institutional research grants from Bayer; he serves as Chairperson of the Scientific Advisory Board of the International Aspirin Foundation. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"49"}}